Pediatric anthrax clinical management.
Anthrax is a zoonotic disease caused by Bacillus anthracis, which has multiple routes of infection in humans, manifesting in different initial presentations of disease. Because B anthracis has the potential to be used as a biological weapon and can rapidly progress to systemic anthrax with high mortality in those who are exposed and untreated, clinical guidance that can be quickly implemented must be in place before any intentional release of the agent. This document provides clinical guidance for the prophylaxis and treatment of neonates, infants, children, adolescents, and young adults up to the age of 21 (referred to as "children") in the event of a deliberate B anthracis release and offers guidance in areas where the unique characteristics of children dictate a different clinical recommendation from adults.
John S
JS
Bradley
Georgina
G
Peacock
Steven E
SE
Krug
William A
WA
Bower
Amanda C
AC
Cohn
Dana
D
Meaney-Delman
Andrew T
AT
Pavia
D000293:Adolescent; D000881:Anthrax / Q000188:drug therapy* / Q000517:prevention & control*; D022122:Anthrax Vaccines / Q000627:therapeutic use; D001408:Bacillus anthracis; D054045:Biological Warfare Agents; D002487:Centers for Disease Control and Prevention, U.S.; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000627:therapeutic use; D004318:Doxycycline / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006266:Health Education; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007318:Inservice Training; D010372:Pediatrics / Q000193:education; D014481:United States; D055815:Young Adult
D022122:Anthrax Vaccines; D054045:Biological Warfare Agents; D002939:Ciprofloxacin; D004318:Doxycycline
anthrax; anthrax vaccine; biological weapon; bioterrorism; children; pediatrics; prophylaxis